DOCSLIB.ORG

Patient Education Handbook As Soon As I Was Diagnosed with Lung Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NAVIGATING LUNG CANCER NAVIGATING LIFE DOESN’T COME WITH INSTRUCTIONS, BUT LIVING WITH LUNG CANCER NOW HAS THIS SURVIVOR’S GUIDEBOOK. NAVIGATING INSIDE YOU WILL GET THE MOST UP-TO-DATE NAVIGATION TOOLS ON: • THE DIAGNOSIS PROCESS • LIVING WITH LUNG CANCER • LUNG CANCER STAGING • FINANCING YOUR CARE LUNG CANCER • TREATMENT OPTIONS • HOPE FOR SURVIVING LUNG CANCER • CLINICAL TRIALS • AND MORE In my house we call it “the lung bible.” It has been an invaluable resource 360º OF HOPE for me, my family and (sadly) a newly diagnosed friend. FIFTH EDITION – FALL 2020 —Diane Broderick I love this handbook! It has great information that I have shared with my family and friends. I often pick it up and re-read. Each time I learn something new, or it triggers something that I need to talk to my doctor(s) about. —Kimberly Buchmeier 360º OF HOPE When my husband was first diagnosed with stage IV Adenocarcinoma we were paralyzed with fear and found ourselves starved for good information about the fight we were beginning. The University of Colorado/ Anchutz hospital advised us to contact the foundation and we were sent this wonderful handbook that answered all of our questions and enabled us to feel knowledgeable when choosing an oncologist and when facing surgery and treatments. It is an invaluable resource to us. —Peter & Donna Blum This is the most comprehensive manual I’ve ever seen written...focused for the lung cancer patient. BONNIE —Roy S. Herbst, MD, PhD BONNIE J. ADDARIO Ensign Professor of Medicine (Oncology), Professor of Pharmacology, Chief of Medical Oncology, Associate Director for Translational Research, Director—Thoracic Oncology SURVIVOR Research Program, Yale Comprehensive Cancer Center, Yale School of Medicine J. ADDARIO SINCE 2003 WWW.GO2FOUNDATION.ORG NAVIGATING LUNG CANCER 360º OF HOPE 5TH EDITION – FALL 2020 PEH(74)ENGLISHINTERIOR(8.625x11.25)RESIZE11320.indd 1 11/3/20 9:27 AM GO2 FOUNDATION FOR LUNG CANCER In April 2019, the Addario Lung Cancer Foundation (ALCF), formerly the Bonnie J. Addario Lung Cancer Foundation, and the Lung Cancer Alliance in Washington, D.C., announced joining forces to become the GO2 Foundation for Lung Cancer. “We are thrilled to blend our talent, resources, commitment, and compassion to create this powerhouse foundation,” said GO2 Foundation co-founder and board chair Bonnie J. Addario.“ The GO2 Foundation will transform what it means to live with lung cancer and increase the patient survival rate of the world’s number one cancer killer annually. Together we will continue to break barriers and save lives.” www.GO2foundation.org PEH(74)ENGLISHINTERIOR(8.625x11.25)RESIZE11320.indd 2 11/3/20 9:27 AM CONTRIBUTORS AUTHORS Bonnie J. Addario, Founder & Survivor Shane P. Dormady, MD, PhD Editor-in-Chief GO2 Foundation for Lung Cancer Valley Medical Oncology Consultants Chief Patient Officer, Danielle Hicks Senior Writer / Editor, Eileen Johnson, RN, MSN, CPHQ Project Manager / Contributing Writer, Alicia Sable-Hunt, RN, MBA AUTHORS / ADVISORY BOARD Lisa Boohar, MD Radiation Oncology, Kaiser Permanente Elizabeth A. David, MD Assistant Professor of Surgery, Thoracic Surgeon at University of California Davis Shane P. Dormady, MD, PhD Director of Thoracic Medical Oncology at El Camino Cancer Center Valley Medical Oncology Consultants David R. Gandara, MD Professor of Medicine at the University of California, Davis School of Medicine and Associate Director of Clinical Research, and Director of Thoracic Oncology UC Davis Comprehensive Cancer Center Paul Hesketh, MD Director of Thoracic Oncology Sophia Gordon Cancer Center and Director of Thoracic Oncology Lahey Clinic Medical Center Richard Lanman, MD Chief Medical Officer, Guardant Health Robert Sinha, MD Medical Director, El Camino Hospital Radiation Oncology CONTRIBUTING AUTHORS Daniel Saez, MSc Navigator, Treatment & Clinical Trials Disclaimer: Information presented in Navigating Lung Cancer 360° of Hope is not intended as a substitute for the advice given by your health care provider. The opinions expressed in Navigating Lung Cancer 360° of Hope are those of the authors. Although Navigating Lung Cancer 360° of Hope strives to present only accurate information, readers should not consider it as professional advice, which can only be given by a health care provider. The GO2 Foundation for Lung Cancer, its authors, and its agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions or inaccuracies in this publication, whether arising from negligence or otherwise or for any consequences arising there from. The GO2 Foundation for Lung Cancer, its authors, and its agents make no representations or warranties, whether express or implied, as to the accuracy, completeness or timeliness of the information contained herein or the results to be obtained from using the information. The GO2 Foundation for Lung Cancer is not engaged in rendering medical or other professional services. The publication of advertisement, whether paid or not, and survivor stories are not an endorsement. If medical or other expert assistance is required the services of a competent professional person should be sought. For Additional Copies: To order additional copies go to www.go2foundation.org, call us at 1-800-298-2436 or email [email protected]. GO2 FOUNDATION FOR LUNG CANCER • 1100 Industrial Road #1 • San Carlos, CA 94070 Design: White Space, Inc. PEH(74)ENGLISHINTERIOR(8.625x11.25)RESIZE11320.indd 3 11/3/20 9:27 AM ACKNOWLEDGMENTS ACKNOWLEDGMENTS The GO2 Foundation for Lung Cancer is proud to publish the 5th Edition of Navigating Lung Cancer 360º of Hope with the most recent advancements and updates to help patients in real time. We are eternally grateful to Dr. Shane Dormady for his leadership and expertise editing this guidebook and to the leading lung cancer clinicians who provided insight and direction on the original content. It is only through the generosity of our supporters that we are able to publish and re-publish this guidebook and offer it free of charge to the lung cancer community, lung cancer patients and their families. For this 5th edition, special thanks goes to Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo, EMD Serono, Foundation Medicine, Genentech, Janssen Oncology, Jazz Pharmaceuticals, Eli Lilly and Company, Merck, Novartis, Regeneron I Sanofi Genzyme, and Takeda. If you or your company would like information on supporting future editions, please contact Andrea Beltramo Parks: [email protected]. PEH ENGLISH 2021 FINAL 51721(2).indd 4 5/17/21 6:49 PM FOREWARD BY DAVID R. GANDARA, MD Dear Patients, I have been with the Bonnie J. Addario Lung Cancer Foundation (ALCF), and now the GO2 Foundation for Lung Cancer, from its beginning in 2006 and I am honored to help them lead patients to the best possible outcomes. If you are holding this handbook or reading it online, you’ve taken the first best step to connecting yourself with the most experienced clinicians worldwide and with a foundation that provides the information you need on your cancer journey. One of the most important resources that we provide is the Living Room. On the third Tuesday of every month, you can tune into the https://go2foundation.org/resources-and-support/lung- cancer-living-room/ to meet other patients who are either exactly where you are or years ahead and LIVING with lung cancer—patients all over the world. I have spoken many times over the years at the Living Room, am a co-author of this handbook, and am part of a team of leaders in lung cancer who support this foundation and its patients. This foundation is a lifeline for many of my patients and we are all here to help you and your family in every way we can. It’s important to know that there are many, many kinds of lung cancer. It’s complex. The way we approach lung cancer today, as opposed to 11 years ago, is through personalized medicine and individualized care, because each of you is different. The pace of advancement and learning new things in lung cancer has never been faster than it is today. More and more, lung cancer is a poster child for all the other cancers where we can take the information from the laboratory and translate it into how we take care of patients. All of us need to have our running shoes on if we’re going to keep up. Today, when something is found in the laboratory it takes less than a year to make its way to the clinic and right to the patient. From the start, getting information must be part of your lung cancer journey. Most of my patients are informed before they come to see me. Sometimes they pick up bad information, but by and large they know a lot. Having knowledgeable patients make decisions together with their doctors, as a partnership, is very positive approach for both patients and physicians. It is important for you to know that often, there are options, not always right or wrong answers. You are a patient who now holds in your hands a resource that is your best first step toward understanding and living with lung cancer. In this book and through the lung cancer Living Room you will become educated, informed and most important…you will find answers, directions, options and HOPE. What we want all our patients to do is live their lives every day to the fullest. Warmly, David R. Gandara, MD Professor of Medicine at the University of California, Davis School of Medicine and Associate Director of Clinical Research, and Director of Thoracic Oncology UC Davis Comprehensive Cancer Center PEH(74)ENGLISHINTERIOR(8.625x11.25)RESIZE11320.indd 5 11/3/20 9:27 AM 29 QUESTIONS TO ASK YOUR ONCOLOGIST AND HEALTHCARE TEAM 1. What type of lung cancer do I have? 2.
Recommended publications
  • Mediastinoscopic Esophagectomy with Lymph Node Dissection Using a Bilateral Transcervical and Transhiatal Pneumomediastinal Approach

    Mediastinoscopic Esophagectomy with Lymph Node Dissection Using a Bilateral Transcervical and Transhiatal Pneumomediastinal Approach

    Tokairin et al. Mini-invasive Surg 2020;4:32 Mini-invasive Surgery DOI: 10.20517/2574-1225.2020.23 Technical Note Open Access Mediastinoscopic esophagectomy with lymph node dissection using a bilateral transcervical and transhiatal pneumomediastinal approach Yutaka Tokairin1,2, Yasuaki Nakajima2, Kenro Kawad2, Akihiro Hoshin2, Takuya Okada2, Toshihiro Matsui2, Kazuya Yamaguchi2, Kagami Nagai2, Yusuke Kinugasa2 1Department of Surgery, Toshima Hospital Tokyo Metropolitan Health and Hospitals Corporation, Tokyo 173-0015, Japan. 2Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8510, Japan. Correspondence to: Dr. Yutaka Tokairin, Department of Surgery, Toshima Hospital Tokyo Metropolitan Health and Hospitals Corporation, 33-1 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan. E-mail: [email protected] How to cite this article: Tokairin Y, Nakajima Y, Kawad K, Hoshin A, Okada T, Matsui T, Yamaguchi K, Nagai K, Kinugasa Y. Mediastinoscopic esophagectomy with lymph node dissection using a bilateral transcervical and transhiatal pneumomediastinal approach. Mini-invasive Surg 2020;4:32. http://dx.doi.org/10.20517/2574-1225.2020.23 Received: 17 Feb 2020 First Decision: 17 Mar 2020 Revised: 24 Mar 2020 Accepted: 1 Apr 2020 Published: 16 May 2020 Science Editor: Itasu Ninomiya Copy Editor: Jing-Wen Zhang Production Editor: Tian Zhang Abstract We developed a method for mediastinoscopic esophagectomy via a bilateral transcervical and transhiatal approach under pneumomediastinum as a less-invasive radical operation. The right recurrent nerve is first identified using an open approach, and the right cervical paraesophageal lymph nodes and part of the right recurrent nerve lymph nodes are dissected, after which pneumomediastinum is initiated.
  • Table of Contents 1

    Table of Contents 1

    GENERAL THORACIC SURGERY DATABASE v.2.3 TRAINING MANUAL January 2018 Table of Contents 1. Demographics ................................................................................................................................................................. 2 2. Follow Up ........................................................................................................................................................................ 9 3. Admission ..................................................................................................................................................................... 10 4. Pre-Operative Evaluation ............................................................................................................................................. 14 5. Diagnosis (Category of Disease) ................................................................................................................................... 49 6. Procedure ..................................................................................................................................................................... 72 7. Post-Operative Events ................................................................................................................................................ 114 8. Discharge .................................................................................................................................................................... 141 9. Quality Measures ......................................................................................................................................................
  • NCCN Guidelines for Patients: Non-Small Cell Lung Cancer

    NCCN Guidelines for Patients: Non-Small Cell Lung Cancer

    NCCN.org/patients/surveyPlease complete our online survey at NCCN Guidelines for Patients® Version 1.2016 Lung Cancer NON–SMALL CELL LUNG CANCER Presented with support from: Available online at NCCN.org/patients Ü NCCN Guidelines for Patients® Version 1.2016 Lung Cancer NON-SMALL CELL LUNG CANCER Learning that you have cancer can be overwhelming. The goal of this book is to help you get the best cancer treatment. It explains which cancer tests and treatments are recommended by experts of non-small cell lung cancer. The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 27 of the world’s leading cancer centers. Experts from NCCN have written treatment guidelines for doctors who treat lung cancer. These treatment guidelines suggest what the best practice is for cancer care. The information in this patient book is based on the guidelines written for doctors. This book focuses on the treatment of non-small cell lung cancer. Key points of the book are summarized in the related NCCN Quick Guide™. NCCN also offers patient resources on lung cancer screening as well as other cancer types. Visit NCCN.org/patients for the full library of patient books, summaries, and other patient and caregiver resources. ® NCCN Guidelines for Patients i Lung Cancer – Non-Small Cell, Version 1.2016 Endorsers and sponsors Endorsed and sponsored in part by LUNG CANCER ALLIANCE LUNG CANCER RESEARCH COUNCIL Lung Cancer Alliance is proud to collaborate with National Comprehensive As an organization that seeks to increase public awareness and Cancer Network to sponsor and endorse these NCCN Guidelines for understanding about lung cancer and support programs for screening and Patients®: Non–Small Cell Lung Cancer.
  • Collaborative Stage Manual Part II

    Collaborative Stage Manual Part II

    SEER Program Coding and Staging Manual 2004, Revision 1 Collaborative Staging Codes Nasal Cavity C30.0 C30.0 Nasal cavity (excludes nose, NOS C76.0) Note: Laterality must be coded for this site, except subsites Nasal cartilage and Nasal septum, for which laterality is coded 0. CS Tumor Size CS Site-Specific Factor 1 - Size of The following tables are available CS Extension Lymph Nodes at the collaborative staging CS TS/Ext-Eval CS Site-Specific Factor 2 - website: CS Lymph Nodes Extracapsular Extension, Lymph Nodes Histology Exclusion Table CS Reg Nodes Eval for Head and Neck AJCC Stage Reg LN Pos CS Site-Specific Factor 3 - Levels I- Lymph Nodes Size Table Reg LN Exam III, Lymph Nodes for Head and Neck CS Mets at DX CS Site-Specific Factor 4 - Levels IV- CS Mets Eval V and Retropharyngeal Lymph Nodes for Head and Neck CS Site-Specific Factor 5 - Levels VI- VII and Facial Lymph Nodes for Head and Neck CS Site-Specific Factor 6 - Parapharyngeal, Parotid, Preauricular, and Sub-Occipital Lymph Nodes, Lymph Nodes for Head and Neck Nasal Cavity CS Tumor Size SEE STANDARD TABLE Nasal Cavity CS Extension Code Description TNM SS77 SS2000 00 In situ; non-invasive Tis IS IS 10 Invasive tumor confined to site of origin T1 L L Meatus (superior, middle, inferior) Nasal chonchae (superior, middle, inferior) Septum Tympanic membrane 30 Localized, NOS T1 L L 40 Extending to adjacent connective tissue within the nasoethomoidal T2 RE RE complex Nasolacrimal duct 60 Adjacent organs/structures including: T3 RE RE Bone of skull Choana Frontal sinus Hard palate
  • Alternative – Universal Extended Video Mediastinoscopy with Distending, Narrow Blades Extended Video Mediastinoscopy with Distending, Tapered Blade System

    Alternative – Universal Extended Video Mediastinoscopy with Distending, Narrow Blades Extended Video Mediastinoscopy with Distending, Tapered Blade System

    THOR 19 2.0 11/2020-E Alternative – Universal Extended video mediastinoscopy with distending, narrow blades Extended video mediastinoscopy with distending, tapered blade system By creating visibility and space, video mediastinoscopy allows the precise display and dissection of mediastinal structures and is therefore valuable for lymph node staging. Mediastinal staging as well as extended or complex endoscopic interventions, including video-assisted mediastinoscopic lymphadenectomy (VAMLA), can be performed with the aid of a distending video mediastinoscope system. KARL STORZ offers an atraumatic, easy-to-use, compact blade system with a holding arm device and an integrated irrigation and suction channel for this purpose. Two adjustment wheels in the handle allow distal distension of the blades and height adjustment in parallel. Combined with a matching HOPKINS® wide angle telescope, this autoclavable blade system provides the operating surgeon with an optimal overview of the working area. In conjunction with a holding arm with KSLOCK, bimanual work is also possible. The corresponding DCI® camera head IMAGE1 S™ D1 is operated via the modular KARL STORZ IMAGE1 S™ camera platform. Consequently, the system is likely to experience a renaissance in the coming years. We also offer instruments and other accessories that are compatible with the system. © KARL STORZ 96082019 THOR 19 2.0 11/2020 EW-E 2 Components of the KARL STORZ video mediastinoscopy system for extended mediastinoscopy Monitor 27" FULL HD Monitor TM220 Camera System IMAGE1 S CONNECT®
  • Mediastinoscopy: a Clinical Evaluation of 400 Consecutive Cases

    Mediastinoscopy: a Clinical Evaluation of 400 Consecutive Cases

    Thorax: first published as 10.1136/thx.24.5.585 on 1 September 1969. Downloaded from Thorax (1969), 24, 585. Mediastinoscopy: A clinical evaluation of 400 consecutive cases C. L. SARIN1 AND H. C. NOHL-OSER From the Thoracic Surgical Unit, Harefield Hospital, Harefield, Middlesex Mediastinoscopy was carried out in 400 cases, including 296 of bronchogenic carcinoma. At the time of presentation the new growth had already spread to involve the mediastinal lymph nodes in slightly more than 50% of these. The incidence of involvement was 76% in oat-cell and 35% in squamous-cell carcinoma. Non-resectability at thoracotomy was encountered in seven out of 120 patients. We advocate this procedure in every case of bronchogenic carcinoma which is considered operable on other counts. In patients in whom the mediastinal lymph nodes are invaded by growth we prefer radical radiotherapy to surgery, as the long-term survival of the two methods is comparable. This procedure may be the only source of positive histological proof of diagnosis, not only in carcinoma but in other types of intrathoracic disease. We believe that this procedure reduces the number of unnecessary exploratory thoracotomies. Carlens (1959) introduced diagnostic exploration sible. Biopsy in such cases can be obtained from tissues inside the thoracic inlet. in the of the superior mediastinum. The space explored just Bleeding, copyright. is part of the superior mediastinum which is presence of incipient or developed superior vena caval of the obstruction, or dense fibrosis of the pre-tracheal situated around tihe intrathoracic part fascia, can make the procedure difficult or impossible.
  • Cervical Mediastinal L SUSAN ALEXANDER L for STAGING of LUNG CANCER

    Cervical Mediastinal L SUSAN ALEXANDER L for STAGING of LUNG CANCER

    Cervical Mediastinal l SUSAN ALEXANDER l FOR STAGING OF LUNG CANCER ervical mediastinal exp- bronchogenic lung cancer by sam- loration (CME), or pling selected lymph nodes in and mediastinoscopy, is a around the trachea, its major surgical procedure to bifurcation and the great vessels. C explore and sample Lymph nodes are removed and lymph nodes in the space between sent to pathology for tissue diag- the lungs, (the mediastinum), nosis to determine the histology when diagnostic imaging studies of the tumor. CME is performed (X-ray, CT scan, etc) suggest a primarily to stage lung cancer growth in the lungs or mediasti- and determine the extent of the nal region. The most common pur- disease and establish treatment pose of the CME is to diagnose options. DECEMBER 2002 The Surgical Technologist 9 224 DECEMBER 2002 CATEGORY 1 If cancer exists in the lymph nodes, the cell type nodes that are not accessible through CME. In (histology) identifies the type of cancer and one series of 100 patients with tumors in this extent of the lymph nodes involved. If tumor area, 22 were found to be inoperable despite hav­ involvement in the mediastinal area is demon­ ing a negative mediastinoscopy.5 Left anterior strated in the pathology review of the speci- mediastinotomy through the second intercostal men(s) (lymph nodes), the patient may be space is the preferred method to assess the oper­ spared an unnecessary thoracotomy; however, ability of these patients, as suggested by Pearson this means that the tumor is inoperable.5 and coworkers.5 Less than 50% of patients undergoing cura­ History tive resection for bronchogenic carcinoma sur­ CME was originally described by Harken and vive five years.
  • Experience with Video Mediastinoscopy at a Tertiary Cancer Center

    Experience with Video Mediastinoscopy at a Tertiary Cancer Center

    Oncology and Radiotherapy © 1 (50) 2020: 001-005 • RESEARCH ARTICLE From radiological assumption to pathological conviction: experience with video mediastinoscopy at a tertiary cancer center Nizamudheen MP, Abhay K Kattepur, Satheesan B Department of Surgical Oncology, Malabar Cancer Centre, Thalassery, Kerala, India Purpose: To describe the role of mediastinoscopy in the setting of mediastinaladenopathy secondary to pulmonary and non-pulmonary cancers. INTRODUCTION Methods: Retrospective analysis of patients undergoing video mediastinoscopy SUMMARY from November 2016 to December 2018 at tertiary cancer center for Cervical mediastinoscopy is a time tested tool for the mediastinaladenopathy from lung cancer and non-pulmonary cancers with invasive staging of mediastinal nodes. Standard cervical mediastinal nodes. mediastinoscopy helpsin approaching lymph node stations viz. Results: Twelve patients were included out of which 11 patients underwent right upper paratracheal (station 2R), right lower paratracheal diagnostic mediastinoscopy. The median age was 58 years. Seven patients had lung cancer. The mean number of nodes sampled was 10.5 (range: (4R), left upper paratracheal (2L), right lower paratracheal 2-28 nodes). Five patients had mediastinaladenopathy from non-pulmonary (4L) and sub-carinal (7). Hilar nodes (station 10) can also cancer like endometrial, oropharyngeal and Hodgkin’s lymphoma. Recurrent laryngeal nerve palsy was noted in one patient. be accessed byexperienced surgeons, although it can be Conclusion: Mediastinoscopy serves as a valuable asset for staging of lung technically challenging. Overall, this procedure is accurate and cancer and in the assessment of suspicious nodes in the setting of non- carries minimal morbidity [1]. The role of mediastinoscopy pulmonary cancers. However, training and expertise is in the need of the hour to prevent redundancy of this valuable procedure.
  • Guidelines on the Diagnosis and Treatment of Primary Lung Cancer (2011)

    Guidelines on the Diagnosis and Treatment of Primary Lung Cancer (2011)

    G U I D E L I N E S Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011) Xiu-yi Zhi1*, Yi-long Wu2*, Hong Bu3, Gang Cheng4, Ying Cheng5, Xiang Du6, Bao-hui Han7, Ge-ning Jiang8, Shun- chang Jiao9, De-ruo Liu10, Lun-xu Liu3, You Lu3, Sheng-lin Ma11, Yuan-kai Shi12, Chang-li Wang13, Jie Wang14, Tian- you Wang1, Yue Yang14, Qing-hua Zhou15, Lung Cancer Diagnosis and Treatment Expert Panel of the Chinese Ministry of Health 1Beijing Lung Cancer Center, Capital Medical University, Beijing; 2Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; 3West China Medical School, West China Hospital, Sichuan University, Chengdu; 4Beijing Hospital, Beijing; 5Cancer Hospital of Jilin Province, Changchun; 6Cancer Hospital of Fudan University, Shanghai; 7Shanghai Chest Hospital, Jiaotong University, Shanghai; 8Shanghai Pulmonary Hospital, Tongji University, Shanghai; 9General Hospital of Chinese People's Liberation Army, Beijing; 10Beijing Sino-Japan Hospital, Beijing; 11Hangzhou Cancer Hospital, Hangzhou; 12Cancer Institute and Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing; 13Tianjin Cancer Hospital, Tianjin Medical University, Tianjin; 14Beijing Cancer Hospital, Peking University, Beijing; 15Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital J Thorac Dis 2012;4:88-101. DOI: 10.3978/j.issn.2072-1439.2010.08.01 Introduction . smoking with a smoking index of greater than 400 cigarettes/ year; a history of high-risk occupational exposure (eg. exposure Primary lung cancer (PLC) is one of the most common to asbestos) and family history of PLC; or at the age of 45 years malignant tumors in China.
  • TNM Classification of Malignant Tumours

    TNM Classification of Malignant Tumours

    Table of Contents Cover Title Page Preface References Acknowledgments Organizations Associated with the TNM System Members of UICC Committees Associated with the TNM System Section Editors Introduction References Head and Neck Tumours Lip and Oral Cavity Pharynx References Larynx Nasal Cavity and Paranasal Sinuses Unknown Primary – Cervical Nodes Malignant Melanoma of Upper Aerodigestive Tract Major Salivary Glands Thyroid Gland Digestive System Tumours Oesophagus Stomach Reference Small Intestine Appendix Colon and Rectum Anal Canal and Perianal Skin Liver Intrahepatic Bile Ducts Gallbladder Perihilar Bile Ducts Distal Extrahepatic Bile Duct Ampulla of Vater Pancreas Well Differentiated Neuroendocrine Tumours of the Gastrointestinal Tract Lung, Pleural, and Thymic Tumours Lung References Pleural Mesothelioma Thymic Tumours References Tumours of Bone and Soft Tissues Bone Soft Tissues Gastrointestinal Stromal Tumour (GIST) Skin Tumours Carcinoma of Skin (excluding eyelid, head and neck, perianal, vulva, and penis) Skin Carcinoma of the Head and Neck Carcinoma of Skin of the Eyelid Malignant Melanoma of Skin Merkel Cell Carcinoma of Skin Breast Tumours Reference Gynaecological Tumours Reference Vulva Vagina Cervix Uteri Uterus – Endometrium Reference Uterine Sarcomas References Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Reference Gestational Trophoblastic Neoplasms Reference Urological Tumours Penis Prostate References Testis Kidney Renal Pelvis and Ureter Urinary Bladder Urethra Adrenal Cortex (ICD O 3 C74.0) Ophthalmic
  • Vascular Spread of Carcinoma of the Bronchus * by H

    Vascular Spread of Carcinoma of the Bronchus * by H

    Thorax: first published as 10.1136/thx.11.3.172 on 1 September 1956. Downloaded from Thorax (1956), 11, 172. AN INVESTIGATION INTO THE LYMPHATIC AND VASCULAR SPREAD OF CARCINOMA OF THE BRONCHUS * BY H. C. NOHL From the London Chest Hospital (RECEIVED FOR PUBLICATION JANUARY 28, 1956) The present investigation was carried out be- Each spezimen while still fresh and unfixed was cause little work has been done to elucidate the carefully cleared of all the visible lymph nodes, and problems concerning the lymphatic spread of their relationship to the nearest bronchus was noted bronchogenic carcinoma. The question, whether and charted on a diagram (Fig. 1). the treatment of carcinoma of the bronchus by Vascular involvement was also looked for and lobectomy rather than by pneumonectomy is p.eces of pulmonary vein were sent for histological examination where invasion seemed most likely. based on sound pathological principles, needed Visceral or parietal pleural infiltration was noted and clarification. It was also felt that the establish- again microscopic confirmation was sought. And, ment of a surgical-pathological classification for lastly, the situation and extent of the growth were the purpose of prognosis and assessment of various carefully recorded. forms of treatment, as has been donz for cancer Each lymph node was then sectioned after fixation copyright. at other sites, was long overdue. Furthermore, and two slides were made of each gland. A serial the anatomy of the intrapulmonary lymphatic section of each lymph node was not done, as it would pathways described in the past are no longer have entailed an insurmountable amount of work.
  • 3D Printed Model of the Mediastinum for Cardiothoracic Surgery Resident Education Natalie S

    3D Printed Model of the Mediastinum for Cardiothoracic Surgery Resident Education Natalie S

    3D printed model of the mediastinum for cardiothoracic surgery resident education Natalie S. Lui MD1, Winston Trope1, H. Henry Guo MD PhD2, Kyle Gifford2, Prasha Bhandari MPH1, Jalen Benson1, Douglas Z. Liou MD1, Leah M. Backhus MD MPH1, Mark F. Berry MD1, Joseph B. Shrager MD1 Divisions of 1Thoracic Surgery and 2Radiology, Stanford University School of Medicine, Stanford, CA Purpose Results Conclusion Mediastinoscopy remains the gold standard for mediastinal lymph node There were 51 resident self assessments and 65 attending assessments completed over A novel, 3D printed model of the mediastinum was an staging, but residents are performing fewer of them with the development of two years. (Residents and attendings could complete more than one assessment). effective tool for teaching cardiothoracic surgery endobronchial ultrasound. We hypothesized that a three-dimensional (3D) General surgery, integrated cardiac residents, and traditional thoracic and cardiac track residents the anatomy and techniques for printed model of the mediastinum would be an effective tool for teaching fellows were included. mediastinoscopy, as measured by resident self assessment and attending assessment. 3D printing is a residents the anatomy and techniques for mediastinoscopy. Residents taught with the 3D model (n=22) were more likely to respond “well” or “very promising technology with many potential applications Methods well” for three of the four self assessment questions. Attendings were more likely to in cardiothoracic surgery resident education. Computed tomography images were segmented using Materialise Mimics respond “very well” to two of the assessment questions. (Figure 4) (Materialise, Leuven, Belgium), and a color model of the mediastinum was Figure 4. Resident self assessments (A) and attending assessments (B) comparing 3D printed using a Stratasys J735 (Stratasys, Eden Prairie, MN).